Loading
A phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer, run by Nancy Lin, MD, now recruiting.
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs is a phase 2, interventional study registered as NCT06176261 by Nancy Lin, MD, with a registry enrolment figure of 58 participants, started 2024-01-08 and due to reach its primary completion in 2028-01-01. Interventions recorded: Datopotamab Deruxtecan. Conditions listed: Breast Cancer; Breast Cancer Female; Metastatic Triple-Negative Breast Carcinoma; ER Positive Breast Cancer; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; ER-negative Breast Cancer. Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Brain metastases (intracranial disease), Datopotamab deruxtecan, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Brain metastases (intracranial disease), Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Brain metastases (intracranial disease), Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Datopotamab deruxtecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Brain metastases (intracranial disease), Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Datopotamab deruxtecan, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/